| Continuous Glucose Monitoring |
1 |
1 |
| Type 2 Diabetes Mellitus |
0 |
0.99 |
| Nutrition |
0 |
0.6 |
| Primary Care |
0 |
0.43 |
| SGLT2 Inhibitor |
0 |
0.35 |
| Diet |
0 |
0.26 |
| Coronary Artery Disease (CAD) |
0 |
0.18 |
| Hyperglycemia |
0 |
0.17 |
| Hypoglycemia |
0 |
0.17 |
| Salary and Compensation |
0 |
0.17 |
| Stress |
0 |
0.17 |
| Sulfonylureas |
0 |
0.17 |
| GLP-1 Receptor Agonist |
0 |
0.15 |
| Congestive Heart Failure |
0 |
0.12 |
| Renal Disease |
0 |
0.12 |
| Cardiovascular Risk Management |
0 |
0.1 |
| Heart Failure (HF) |
0 |
0.1 |
| Calcaneal |
0 |
0.09 |
| Cardiovascular disease |
0 |
0.09 |
| Clinical Guidelines |
0 |
0.09 |
| Clinical Research |
0 |
0.09 |
| Endocrinology |
0 |
0.09 |
| Grant |
0 |
0.09 |
| Heart |
0 |
0.09 |
| Insulin Therapy |
0 |
0.09 |
| Kidney |
0 |
0.09 |
| Receptors |
0 |
0.09 |
| Salvage Therapy |
0 |
0.09 |
| Revenue and Practice Management |
0 |
0.08 |
| Chronic Kidney Disease |
0 |
0.07 |
| Renal Failure |
0 |
0.07 |